Multiple drugs

Abstract

No improvement: 5 case reports In a retrospective study involving 16 patients, 5 women, aged 26–61 years were described, who exhibited no improvement during treatment with rituximab, immune globulin, mycophenolate or methylprednisolone for musicogenic epilepsy [dosages not stated; not all routes stated]. Patient 2 (from table 1 of the article): The 36-year-old woman exhibited no improvement during treatment with mycophenolate for musicogenic epilepsy. The woman with thyroid disease, had country type musicogenic epilepsy. She was high-titer GAD65-IgG seropositive. She underwent vagus nerve stimulator with 50% reduction in seizure frequency. Thereafter, she was treated with mycophenolate and methylprednisolone. However, she had no improvement with mycophenolate. She showed reduction in her seizures with methylprednisolone. At the last follow-up, she had seizure frequency of 10 seizures per month. Patient 3 (from table 1 of the article): The 31-year-old woman exhibited no improvement during treatment with rituximab for musicogenic epilepsy. She was diagnosed with epilepsy at the age of 17 years. She had cognitive concerns and pop type musicogenic epilepsy. She also exhibited bilateral tonic-clonic seizures. She was high-titer GAD65-IgG seropositive. She underwent right temporal lobectomy and responsive neurostimulation for seizures device; however, no improvement was noted. Therefore, she was treated with rituximab. However, she had no improvement in seizure activity with rituximab therapy. At the last follow-up, she had seizure frequency of 6–7 seizures per month. Patient 5 (from table 1 of the article): The 61-year-old woman exhibited no improvement during treatment with immune globulin for musicogenic epilepsy. The woman, who had thyroid disease, had epilepsy onset at the age of 46 years. She had melancholic, church and hymns type musicogenic epilepsy. She also exhibited bilateral tonic-clonic seizure activity. She was high-titer GAD65-IgG seropositive. She was treated with IV immune globulin [IVIG]. However, she showed no improvement in the seizure activity. Later, her seizure activity improved by avoiding music. At the last follow-up, she had rare seizure frequency with provoking music. Patient 6 (from table 1 of the article): The 26-year-old woman exhibited no improvement during treatment with methylprednisolone and immune globulin for musicogenic epilepsy. The woman, who had type 1 diabetes mellitus and thyroid disease, had epilepsy onset at the age of 23 years. She had pop and soft rock type musicogenic epilepsy. She was high-titer GAD65-IgG seropositive. She was treated with IV immune globulin [IVIG] and IV methylprednisolone. However, she showed no improvement in seizure activity with immune globulin and methylprednisolone. Patient 8 (from table 1 of the article): The 36-year-old woman exhibited no improvement during treatment with rituximab, methylprednisolone and immune globulin for musicogenic epilepsy. The woman, who had stiff person syndrome and pernicious anemia, had epilepsy onset at the age of 34 years. She had cognitive concerns and had pop and techno type musicogenic epilepsy. She was high-titer GAD65-IgG seropositive. She was treated with rituximab, IV immune globulin [IVIG] and IV methylprednisolone. However, she showed no improvement in the seizure activity. At the last follow-up, she had seizure frequency of one seizure per day with some improvement with ketogeneic diet.